|Slideshows|January 13, 2022

The 7 new drugs expected to hit $1 billion in sales in five years

These drugs treat everything from cancer to cognitive decline.

Pharmaceutical companies never stop developing new drugs to treat a wide variety of ailments. The analytics firm Clarivate issued a report outlining which drugs it projects will hit $1 billion in sales in the next five years.

Here are the seven drugs with the biggest potential.

Newsletter

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!

Related Content

Morning Medical Update © meeboonstudio - stock.adobe.com

Lab to pay $758,000 in kickback case; fungal compound shows promise against brain cancer; losing sleep over climate change – Morning Medical Update

ByAustin Littrell

December 5th 2025

vaccines: © peterschreiber.media - stock.adobe.com

ACIP and the hepatitis B vaccine: recommendations, mandates and patient informed consent

ByRichard Payerchin

December 4th 2025

ACIP postpones vote on hepatitis B vaccines at birth

ByRichard Payerchin

December 4th 2025

In defense of private equity, with Jared Rhoads, M.S., M.P.H., of the Center for Modern Health

ByAustin Littrell

December 4th 2025

MedPAC signals modest 2027 physician payment bump as staff report strong access, rising revenues

ByAustin Littrell

December 4th 2025

Latest CME

Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

The 7 new drugs expected to hit $1 billion in sales in five years

Newsletter

Related Content

Lab to pay $758,000 in kickback case; fungal compound shows promise against brain cancer; losing sleep over climate change – Morning Medical Update

ACIP and the hepatitis B vaccine: recommendations, mandates and patient informed consent

ACIP postpones vote on hepatitis B vaccines at birth

In defense of private equity, with Jared Rhoads, M.S., M.P.H., of the Center for Modern Health

MedPAC signals modest 2027 physician payment bump as staff report strong access, rising revenues

Latest CME

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Medical Economics

Physicians taking back medicine: The rising toll of private equity in health care

ACIP and the hepatitis B vaccine: recommendations, mandates and patient informed consent

MedPAC signals modest 2027 physician payment bump as staff report strong access, rising revenues

ACIP relies on evidence, transparency, critical reviews, vice chair says

ACIP postpones vote on hepatitis B vaccines at birth